Skip to ContentSkip to Navigation
About us Practical matters How to find us E.A.M. Festen

Publications

Exploring the Predictive Value of Gut Microbiome Signatures for Therapy Intensification in Patients With Inflammatory Bowel Disease: A 10-Year Follow-up Study

Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease

Gut microbial metabolism of 5-aminosalicylic acid in inflammatory bowel disease

Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease

Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial

Health-related quality of life is linked to the gut microbiome in kidney transplant recipients

Health-Related Quality of Life is Linked to the Gut Microbiome in Kidney Transplant Recipients

Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab

HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis

Phage-display immunoprecipitation sequencing of the antibody epitope repertoire in inflammatory bowel disease reveals distinct antibody signatures

Read more

Press/media

Effectiviteit van medicijnen voorspellen bij chronische darmziekte colitis ulcerosa